3 recruiting, 1 unknown. 2 Phase 1, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Early Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Acute Myeloid Leukemia Recurrent: new trials by email Literature Review of Acute Myeloid Leukemia Recurrent trials Research Report on Acute Myeloid Leukemia Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CIML NK Cells With Venetoclax for AML Cytokine-Induced Memory-like Natural Killer Cells, Interleukin-2, Venetoclax - Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent | Phase 1 | Recruiting | Dana-Farber Cancer Institute | 10 | 2024-02-20 | 2026-08-28 |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML Ziftomenib, Venetoclax, Azacitidine - Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation | Phase 1 | Recruiting | Kura Oncology, Inc. | 420 | 2023-07-18 | 2026-03-13 |
| Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia CD123-CAR-NK cells - Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia Recurrent | Early Phase 1 | Unknown | Affiliated Hospital to Academy of Military Medical Sciences | 12 | 2022-10-01 | 2023-04-26 |
| CLAG-GO for Patients With Persistent, Relapsed or Refractory AML Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO) - Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia Recurrent | Phase 2 | Recruiting | University of Maryland, Baltimore | 39 | 2019-11-01 | 2026-07-01 |
Leukemia, Myeloid, Acute (3) · Leukemia (2) · Hematologic Neoplasms (1) · Leukemia, Myeloid (1) · Recurrence (1) · Sarcoma, Myeloid (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Leukemia, Myeloid (2) · Disease Attributes (1) · Leukemia (1) · Neoplasms by Site (1) · Neoplasms, Connective and Soft Tissue (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Sarcoma (1)
Cytarabine (2) · venetoclax (2) · Azacitidine (1) · Cladribine (1) · Daunorubicin (1) · Gemtuzumab (1) · Granulocyte Colony-Stimulating Factor (1) · Interleukin-2 (1) · aldesleukin (1) · quizartinib (1)
Affiliated Hospital to Academy of Military Medical Sciences (1) · Dana-Farber Cancer Institute (1) · Kura Oncology, Inc. (1) · University of Maryland, Baltimore (1)
United States (3) · China (1)
Evan Chen, MD (1) · Liangding Hu, Docotr (1) · Vu H. Duong, MD, MS (1)